ACM Research (NASDAQ:ACMR) Stock

ACM Research

ACM Research Inc supplies advanced, innovative capital equipment developed for the global semiconductor industry. Fabricators of advanced integrated circuits, or chips, can use its wet-cleaning and other front-end processing tools in numerous steps to improve product yield, even at increasingly advanced process nodes. It has designed these tools for use in fabricating foundry, logic and memory chips, including dynamic random-access memory, or DRAM, and 3D NAND-flash memory chips. The company also develops, manufactures and sells advanced packaging tools to wafer assembly and packaging customers.

ACM Research, Inc. - Class A Common Stock

ACM Research Inc

<p>Scotiabank  analyst Phil Hardie   maintains Fairfax Financial Hldgs (TSX:<a class="ticker" href="https://www.benzinga.com/stock/FFH#TSX">FFH</a>) with a Sector Outperform and raises the price target from C$2400 to C$2500.</p>


News

Price Target

Analyst Ratings

TSX:FFH

Scotiabank Maintains Sector Outperform on Fairfax Financial Hldgs, Raises Price Target to C$2500

<p><a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.isolerebio.com%2F&amp;esheet=54243241&amp;newsitemid=20250424252130&amp;lan=en-US&amp;anchor=Isolere+Bio+by+Donaldson&amp;index=1&amp;md5=3db5e8d0847384827cd19b0b45763e74">Isolere Bio by Donaldson</a>, an innovative bioprocessing technology provider, proudly announces the availability of its manufacturing-grade IsoTag&#x2122; AAV reagent for the purification of Adeno-associated Virus (AAV) vectors. As indicated <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.isolerebio.com%2Farticles%2Fresearch-grade-isotag-aav-reagent-announcement&amp;esheet=54243241&amp;newsitemid=20250424252130&amp;lan=en-US&amp;anchor=during+the+launch+of+the+research-grade+reagent&amp;index=2&amp;md5=2fe070e9555e7100349c16f41a752593">during the launch of the research-grade reagent</a> in October 2024, this final advancement in product grade now includes production with validated processes and the availability of a full suite of documentation, including a Regulatory Support File (RSF), validation guide and full design history upon customer request. Additionally, the U.S. Food and Drug Administration (FDA) has acknowledged its receipt of the recently submitted Drug Master File (DMF) for the IsoTag&#x2122; AAV reagent, which will support and streamline clinical manufacturing using the reagent.</p>
<p><br />&nbsp;</p>


Isolere Bio By Donaldson Announces Availability Of Manufacturing-grade IsoTag AAV Reagent For Purification Of AAV Vectors

WIIM

DGICA

Donegal Group shares are trading higher after the company reported better-than-expected Q1 adjusted EPS results.

<p>POSCO Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PKX#NYSE">PKX</a>) reported quarterly earnings of $0.64 per share. This is a 70.51 percent decrease over earnings of $2.17 per share from the same period last year.  The company reported $12.01 billion in sales this quarter. This is a 20.97 percent decrease over sales of $15.20 billion the same period last year.</p>


Earnings

POSCO Holdings Q1 EPS $0.64 Down From $2.17 YoY, Sales $12.01B Down From $15.20B YoY

<p><strong>Sanofi SA&nbsp;</strong>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>) reported Thursday a first-quarter 2025 business operating income of 2.9 billion euros ($3.06 billion), up 20.1% year over year and <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">18.7%&nbsp;in constant currency</a>.</p>
<p>The company&nbsp;<a target="_blank" href="https://www.sanofi.com/en/media-room/press-releases/2025/2025-04-24-05-30-00-3067075" rel="noreferrer noopener">reported</a> first-quarter sales of 9.89 billion euros ($10.42 billion), beating the <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of $9.77 billion</a>. This was driven by launches, Dupixent, and favorable Beyfortus phasing.</p>
<p>Sales increased 10.8% year over year and 9.7% on constant currency. U.S. sales were 4.66 billion and increased by 15.4%.</p>
<p>The performance was driven by pharma launches, Dupixent, and Lantus, while legacy medicines were lower. Vaccine sales were broadly stable, including lower sales of Beyfortus.</p>
<p><strong>Also Read: <em><a target="_blank" href="https://www.benzinga.com/general/biotech/25/04/44822758/sanofi-asthma-drug-misses-primary-goal-plans-for-pivotal-study" rel="noreferrer noopener">Sanofi Asthma Drug Misses Primary Goal, Plans For Pivotal Study</a></em></strong></p>
<p>The French drugmaker reported adjusted EPS of 1.79 euros or 94 cents per ADS, missing the consensus of 95 cents, up 17% (+15.7% on constant currency).</p>
<p>Sales of Dupixent, Sanofi&#8217;s blockbuster eczema drug, rose 20.3% to 3.5 billion euros due to strong volume growth across all indications and regions. The first COPD launches are underway.</p>
<p>Pharma launches increased 43.8% to 847 million euros, led by Altuviiio (hemophilia&nbsp;drug), Nexviazyme (Pompe disease), Sarclisa (multiple myeloma), and Rezurock (chronic graft-versus-host disease).</p>
<p>Vaccine sales were up 11.4% to 1.3 billion euros, driven by favorable Beyfortus (RSV) phasing and geographical roll-out.</p>
<p>Beyfortus sales were 284 million euros, driven by additional sales in the Northern Hemisphere, particularly Germany and Japan.</p>
<p>Polio/Pertussis/Hib (PPH) primary and booster vaccine sales were 668 million euros and increased by 3.8%, primarily due to demand for boosters to re-vaccinate adolescents and adults.</p>
<p>&#8220;We had a strong start in 2025 with sales growth of 9.7%, benefiting from investments in innovation and a favorable base of comparison. Our focus on pipeline value delivered further growth for Sanofi with sales from launches of new medicines and vaccines growing by 46.5%,&#8221; said Paul Hudson, Chief Executive Officer.</p>
<p><strong>Guidance:</strong> Sanofi <a target="_blank" href="https://www.sanofi.com/assets/dotcom/content-app/events/quaterly-results/2025/2025-q1-2025-results/2025_04_24_Sanofi_Q1_2025_Results.pdf" rel="noreferrer noopener">confirmed</a> its 2025 guidance. In 2025, sales are anticipated to grow by a mid-to-high single-digit percentage at CER.</p>
<p>Sanofi confirms the expectation of a strong rebound in business EPS with growth at a low double-digit level.</p>
<p>On Wednesday, <strong>Innate Pharma SA</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IPHA#NASDAQ">IPHA</a>) <a target="_blank" href="https://www.businesswire.com/news/home/20250422582040/en/Innate-Pharma-Regains-Its-Rights-on-CD123-Targeting-ANKET-and-Announces-Sanofis-Intention-to-Make-a-Strategic-Investment-in-the-Company" rel="noreferrer noopener">reviewed</a> their January 2016 Research Collaboration and License Agreement with Sanofi:</p>
<ul>
<li>As previously disclosed and in alignment with its current strategic priorities, Sanofi will opt to pursue the development of SAR&#8217;514/IPH6401 (BCMA ANKET) in autoimmune indications under the agreement.</li>
<li>Additionally, Sanofi and Innate agreed to terminate the 2016 Agreement regarding SAR&#8217;579/IPH6101 (CD123 ANKET); Innate will regain its rights on SAR&#8217;579/IPH6101.</li>
</ul>
<p>As part of these discussions, Sanofi and Innate have agreed to Sanofi&#8217;s potential investment of up to 15 million euros in new shares of Innate. If the ongoing market conditions are satisfactory, the size and price of this equity investment will be determined.</p>
<p><strong>Price Action</strong>: SNY stock is down 0.83% to $52.58 at the last check on Thursday.</p>
<p><strong>Read Next:</strong></p>
<ul>
<li><strong><em><a href="https://www.benzinga.com/news/earnings/25/04/44977669/pepsico-ceo-warns-of-tariffs-led-increase-in-supply-chain-costs-cuts-annual-profit-outlook" target="_blank" rel="noreferrer noopener">PepsiCo CEO Warns Of Tariffs Led &#8216;Increase In Supply Chain Costs,&#8217; Cuts Annual Profit Outlook</a></em></strong></li>
</ul>
<p><em>Photo by HJBC via Shutterstock</em></p>


Biotech

Large Cap

Guidance

Health Care

General

IPHA

French Drugmaker Sanofi Clocks 20% Q1 Profit Growth, Forecasts Strong Rebound In Annual Profit

AMTB

Amerant Bancorp shares are trading lower after the company reported a Q1 adjusted EPS miss and Raymond James downgraded the stock from Outperform to Market Perform.

<p>JMP Securities  analyst Brian McKenna   reiterates Blackstone (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BX#NYSE">BX</a>) with a Market Outperform and maintains $165 price target.</p>


Reiteration

JMP Securities Reiterates Market Outperform on Blackstone, Maintains $165 Price Target

<p><strong>Portland Gen Electric</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/POR#NYSE">POR</a>) is set to give its latest quarterly earnings report on Friday, 2025-04-25. Here's what investors need to know before the announcement.</p>
<p>Analysts estimate that Portland Gen Electric will report an <strong>earnings per share</strong> (EPS) of $1.14. </p>
<p>The announcement from Portland Gen Electric is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.</p>
<p>It's worth noting for new investors that guidance can be a key determinant of stock price movements.</p>
<h3>Earnings History Snapshot</h3>
<p>In the previous earnings release, the company beat EPS by $0.01, leading to a 0.0% drop in the share price the following trading session.</p>
<p>Here's a look at Portland Gen Electric's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.35</td>
<td>0.87</td>
<td>0.62</td>
<td>1.09</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.36</td>
<td>0.90</td>
<td>0.69</td>
<td>1.21</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-1.0%</td>
<td>-1.0%</td>
<td>-1.0%</td>
<td>-1.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1745503326_0.png" alt="eps graph" /></p>
<h3>Portland Gen Electric Share Price Analysis</h3>
<p>Shares of Portland Gen Electric were trading at $43.32 as of April 23. Over the last 52-week period, shares are up 0.4%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<h3>Analyst Observations about Portland Gen Electric</h3>
<p>For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding Portland Gen Electric.</p>
<p>Analysts have provided Portland Gen Electric with 6 ratings, resulting in a consensus rating of Neutral. The average one-year price target stands at $45.67, suggesting a potential 5.42% upside.</p>
<h3>Analyzing Ratings Among Peers</h3>
<p>In this analysis, we delve into the analyst ratings and average 1-year price targets of TXNM Energy, Idacorp and MGE Energy, three key industry players, offering insights into their relative performance expectations and market positioning.</p>
<ul>
<li>Analysts currently favor an Outperform trajectory for TXNM Energy, with an average 1-year price target of $54.67, suggesting a potential 26.2% upside.</li>
<li>Analysts currently favor an Neutral trajectory for Idacorp, with an average 1-year price target of $124.5, suggesting a potential 187.4% upside.</li>
<li>Analysts currently favor an Underperform trajectory for MGE Energy, with an average 1-year price target of $80.0, suggesting a potential 84.67% upside.</li>
</ul>
<h3>Insights: Peer Analysis</h3>
<p>The peer analysis summary offers a detailed examination of key metrics for TXNM Energy, Idacorp and MGE Energy, providing valuable insights into their respective standings within the industry and their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Portland Gen Electric</td>
<td>Neutral</td>
<td>13.66%</td>
<td>$367M</td>
<td>1.02%</td>
</tr>
<tr>
<td>TXNM Energy</td>
<td>Outperform</td>
<td>15.74%</td>
<td>$293.21M</td>
<td>0.63%</td>
</tr>
<tr>
<td>Idacorp</td>
<td>Neutral</td>
<td>-3.36%</td>
<td>$43.13M</td>
<td>1.15%</td>
</tr>
<tr>
<td>MGE Energy</td>
<td>Underperform</td>
<td>4.11%</td>
<td>$61.54M</td>
<td>1.82%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>Portland Gen Electric is positioned in the middle among its peers for consensus rating. It ranks at the top for revenue growth, indicating strong performance in this area. In terms of gross profit, it is also at the top compared to its peers. However, its return on equity is at the bottom when compared to the other companies in the analysis.</p>
<h3>Delving into Portland Gen Electric's Background</h3>
<p>Portland General Electric is a regulated electric utility providing generation, transmission, and distribution services in a service territory that includes about half of all Oregon residents and two thirds of the state's business activity. The company owns (wholly or through joint ventures) 3.5 gigawatts of gas, coal, wind, and hydro generation.</p>
<h3>Financial Milestones: Portland Gen Electric's Journey</h3>
<p><strong>Market Capitalization Analysis:</strong> The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.</p>
<p><strong>Revenue Growth:</strong> Over the 3 months period, Portland Gen Electric showcased positive performance, achieving a revenue growth rate of <strong>13.66%</strong> as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Utilities sector.</p>
<p><strong>Net Margin:</strong> Portland Gen Electric's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of <strong>4.61%,</strong> the company may encounter challenges in effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> Portland Gen Electric's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of <strong>1.02%,</strong> the company may face hurdles in generating optimal returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> Portland Gen Electric's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of <strong>0.31%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Debt Management:</strong> Portland Gen Electric's debt-to-equity ratio is notably higher than the industry average. With a ratio of <b>1.27</b>, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.</p>
<p><a href="https://www.benzinga.com/quote/POR/earnings"><strong>To track all earnings releases for Portland Gen Electric visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


A Preview Of Portland Gen Electric's Earnings

<p><strong>Trinet Group</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TNET#NYSE">TNET</a>) is set to give its latest quarterly earnings report on Friday, 2025-04-25. Here's what investors need to know before the announcement.</p>
<p>Analysts estimate that Trinet Group will report an <strong>earnings per share</strong> (EPS) of $1.61. </p>
<p>Investors in Trinet Group are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.</p>
<p>It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.</p>
<h3>Historical Earnings Performance</h3>
<p>Last quarter the company beat EPS by $0.19, which was followed by a 1.15% drop in the share price the next day.</p>
<p>Here's a look at Trinet Group's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.25</td>
<td>1.31</td>
<td>1.28</td>
<td>2.46</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.44</td>
<td>1.17</td>
<td>1.53</td>
<td>2.16</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-1.0%</td>
<td>-12.0%</td>
<td>2.0%</td>
<td>-17.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1745503317_0.png" alt="eps graph" /></p>
<h3>Performance of Trinet Group Shares</h3>
<p>Shares of Trinet Group were trading at $76.83 as of April 23. Over the last 52-week period, shares are down 28.17%.  Given that these returns are generally negative, long-term shareholders are likely unhappy going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/TNET/earnings"><strong>To track all earnings releases for Trinet Group visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


TNET

A Preview Of Trinet Group's Earnings

AMBP

Ardagh Metal Packaging shares are trading higher after the company reported a year-over-year increase in Q1 adjusted EPS results and better-than-expected revenue results. Additionally, the company raised its FY25 adjusted EBITDA guidance.

<p><i>Partnership furthers access and affordability of specialty medications and offers personalized support for those with chronic and rare conditions</i></p>
<p>Lumicera Health Services, a specialty pharmacy solutions company, today announced a partnership with Costco Wholesale Corporation (Costco) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COST#NASDAQ">COST</a>) to expand cost-plus specialty pharmacy in the marketplace and offer a broad spectrum of specialty medications with unmatched patient support, pricing transparency, and clinical expertise. Through this collaboration, commercial employer benefit plan sponsors and Pharmacy Benefit Managers (PBMs) that partner with Costco Pharmacy for cost-plus pharmacy will gain access to these complex- and often very expensive- medication therapies at an auditable cost.</p>


COST

Lumicera Health Services And Costco Partner To Expand Cost-plus Specialty Pharmacy In Marketplace

<p>LyondellBasell Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LYB#NYSE">LYB</a>) will release its quarterly earnings report on Friday, 2025-04-25. Here's a brief overview for investors ahead of the announcement.</p>
<p>Analysts anticipate LyondellBasell Industries to report an <strong>earnings per share</strong> (EPS) of $0.43.</p>
<p>Anticipation surrounds LyondellBasell Industries's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.</p>
<p>New investors should understand that while earnings performance is important, market reactions are often driven by guidance.</p>
<h3>Overview of Past Earnings</h3>
<p>Last quarter the company beat EPS by $0.05, which was followed by a 0.0% drop in the share price the next day.</p>
<p>Here's a look at LyondellBasell Industries's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.70</td>
<td>1.98</td>
<td>2.27</td>
<td>1.36</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.75</td>
<td>1.88</td>
<td>2.24</td>
<td>1.53</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-1.0%</td>
<td>-0.0%</td>
<td>-4.0%</td>
<td>2.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1745503304_0.png" alt="eps graph" /></p>
<h3>Stock Performance</h3>
<p>Shares of LyondellBasell Industries were trading at $57.78 as of April 23. Over the last 52-week period, shares are down 42.91%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/LYB/earnings"><strong>To track all earnings releases for LyondellBasell Industries visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


A Glimpse of LyondellBasell Industries's Earnings Potential

<p>Avantor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AVTR#NYSE">AVTR</a>) is gearing up to announce its quarterly earnings on Friday, 2025-04-25. Here's a quick overview of what investors should know before the release.</p>
<p>Analysts are estimating that Avantor will report an <strong>earnings per share</strong> (EPS) of $0.23.</p>
<p>Avantor bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Overview of Past Earnings</h3>
<p>Last quarter the company beat EPS by $0.01, which was followed by a 0.0% drop in the share price the next day.</p>
<p>Here's a look at Avantor's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.26</td>
<td>0.25</td>
<td>0.23</td>
<td>0.20</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.27</td>
<td>0.26</td>
<td>0.25</td>
<td>0.22</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-12.0%</td>
<td>-4.0%</td>
<td>12.0%</td>
<td>-5.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1745503297_0.png" alt="eps graph" /></p>
<h3>Market Performance of Avantor's Stock</h3>
<p>Shares of Avantor were trading at $15.47 as of April 23. Over the last 52-week period, shares are down 36.36%. Given that these returns are generally negative, long-term shareholders are likely upset going into this earnings release. </p>
<h3>Analyst Views on Avantor</h3>
<p>Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the latest insights on Avantor.</p>
<p>Analysts have given Avantor a total of 10 ratings, with the consensus rating being Outperform. The average one-year price target is $23.8, indicating a potential 53.85% upside.</p>
<h3>Peer Ratings Overview</h3>
<p>The analysis below examines the analyst ratings and average 1-year price targets of Revvity, Illumina and Tempus AI, three significant industry players, providing valuable insights into their relative performance expectations and market positioning.</p>
<ul>
<li>Analysts currently favor an Outperform trajectory for Revvity, with an average 1-year price target of $128.17, suggesting a potential 728.51% upside.</li>
<li>Analysts currently favor an Neutral trajectory for Illumina, with an average 1-year price target of $129.4, suggesting a potential 736.46% upside.</li>
<li>Analysts currently favor an Buy trajectory for Tempus AI, with an average 1-year price target of $63.78, suggesting a potential 312.28% upside.</li>
</ul>
<h3>Analysis Summary for Peers</h3>
<p>The peer analysis summary offers a detailed examination of key metrics for Revvity, Illumina and Tempus AI, providing valuable insights into their respective standings within the industry and their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Avantor</td>
<td>Outperform</td>
<td>-2.10%</td>
<td>$562.90M</td>
<td>8.70%</td>
</tr>
<tr>
<td>Revvity</td>
<td>Outperform</td>
<td>4.81%</td>
<td>$412.29M</td>
<td>1.21%</td>
</tr>
<tr>
<td>Illumina</td>
<td>Neutral</td>
<td>-1.60%</td>
<td>$728M</td>
<td>8.31%</td>
</tr>
<tr>
<td>Tempus AI</td>
<td>Buy</td>
<td>35.85%</td>
<td>$122.06M</td>
<td>-23.65%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>Avantor ranks at the top for Gross Profit and Return on Equity among its peers. It is in the middle for Revenue Growth.</p>
<h3>All You Need to Know About Avantor</h3>
<p>Avantor Inc provider of products and services to customers in the biopharma, healthcare, education &amp; government, and advanced technologies &amp; applied materials industries. The company has three geographic segments: the Americas, Europe, and AMEA. The company's product group consists of Equipment &amp; instrumentation, Services &amp; specialty procurement, Proprietary materials &amp; consumables, and Third-party materials &amp; consumables. Materials &amp; consumables include high-purity chemicals and reagents, lab products and supplies, specialized formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, and education and microbiology and clinical trial kits, peristaltic pumps and fluid handling tips.</p>
<h3>Avantor's Financial Performance</h3>
<p><strong>Market Capitalization Analysis:</strong> The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.</p>
<p><strong>Decline in Revenue:</strong> Over the 3 months period, Avantor faced challenges, resulting in a decline of approximately <strong>-2.1%</strong> in revenue growth as of 31 December, 2024. This signifies a reduction in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> Avantor's net margin excels beyond industry benchmarks, reaching <strong>29.67%</strong>. This signifies efficient cost management and strong financial health.</p>
<p><strong>Return on Equity (ROE):</strong> Avantor's ROE stands out, surpassing industry averages. With an impressive ROE of <strong>8.7%</strong>, the company demonstrates effective use of equity capital and strong financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of <strong>4.01%,</strong> the company showcases effective utilization of assets.</p>
<p><strong>Debt Management:</strong> Avantor's debt-to-equity ratio is below the industry average. With a ratio of <b>0.68</b>, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.</p>
<p><a href="https://www.benzinga.com/quote/AVTR/earnings"><strong>To track all earnings releases for Avantor visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


AVTR

An Overview of Avantor's Earnings

<p>SLB (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLB#NYSE">SLB</a>) is gearing up to announce its quarterly earnings on Friday, 2025-04-25. Here's a quick overview of what investors should know before the release.</p>
<p>Analysts are estimating that SLB will report an <strong>earnings per share</strong> (EPS) of $0.73.</p>
<p>SLB bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Past Earnings Performance</h3>
<p>The company's EPS beat by $0.02 in the last quarter, leading to a 0.0% drop in the share price on the following day.</p>
<p>Here's a look at SLB's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.90</td>
<td>0.88</td>
<td>0.83</td>
<td>0.69</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.92</td>
<td>0.89</td>
<td>0.85</td>
<td>0.75</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>6.0%</td>
<td>-5.0%</td>
<td>2.0%</td>
<td>-2.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1745503288_0.png" alt="eps graph" /></p>
<h3>Tracking SLB's Stock Performance</h3>
<p>Shares of SLB were trading at $34.03 as of April 23. Over the last 52-week period, shares are down 29.94%. Given that these returns are generally negative, long-term shareholders are likely upset going into this earnings release. </p>
<h3>Analyst Observations about SLB</h3>
<p>For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding SLB.</p>
<p>With 5 analyst ratings, SLB has a consensus rating of Outperform. The average one-year price target is $52.4, indicating a potential 53.98% upside.</p>
<h3>Peer Ratings Overview</h3>
<p>In this analysis, we delve into the analyst ratings and average 1-year price targets of Baker Hughes, Halliburton and TechnipFMC, three key industry players, offering insights into their relative performance expectations and market positioning.</p>
<ul>
<li>Analysts currently favor an Outperform trajectory for Baker Hughes, with an average 1-year price target of $52.4, suggesting a potential 53.98% upside.</li>
<li>Analysts currently favor an Outperform trajectory for Halliburton, with an average 1-year price target of $29.33, suggesting a potential 13.81% downside.</li>
<li>Analysts currently favor an Outperform trajectory for TechnipFMC, with an average 1-year price target of $39.33, suggesting a potential 15.57% upside.</li>
</ul>
<h3>Analysis Summary for Peers</h3>
<p>In the peer analysis summary, key metrics for Baker Hughes, Halliburton and TechnipFMC are highlighted, providing an understanding of their respective standings within the industry and offering insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Schlumberger</td>
<td>Outperform</td>
<td>3.27%</td>
<td>$1.96B</td>
<td>5.14%</td>
</tr>
<tr>
<td>Baker Hughes</td>
<td>Outperform</td>
<td>-12.72%</td>
<td>$1.53B</td>
<td>2.36%</td>
</tr>
<tr>
<td>Halliburton</td>
<td>Outperform</td>
<td>-3.44%</td>
<td>$1.03B</td>
<td>1.95%</td>
</tr>
<tr>
<td>TechnipFMC</td>
<td>Outperform</td>
<td>13.94%</td>
<td>$387M</td>
<td>7.07%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>SLB ranks first in revenue growth among its peers. It also leads in gross profit and return on equity.</p>
<h3>All You Need to Know About SLB</h3>
<p>SLB is the world's premier oilfield-services company as measured by market share. While the industry is mostly fragmented, SLB holds the first or second competitive position in many of the differentiated oligopolies it operates in. Also known as Schlumberger, the company was founded in 1926 by two brothers bearing the same last name. Today it's most known as a global industry leader in innovation, while it focuses its strategy on its three growth engines: its core, digital, and new energy businesses. Over three fourths of its revenue base is tied to international markets, while the company boasts roughly $3 billion in digital-related revenue.</p>
<h3>Financial Insights: SLB</h3>
<p><strong>Market Capitalization Highlights:</strong> Above the industry average, the company's market capitalization signifies a significant scale, indicating strong confidence and market prominence.</p>
<p><strong>Positive Revenue Trend:</strong> Examining SLB's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of <strong>3.27%</strong> as of 31 December, 2024, showcasing a substantial increase in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Energy sector.</p>
<p><strong>Net Margin:</strong> SLB's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>11.79%</strong> net margin, the company effectively manages costs and achieves strong profitability.</p>
<p><strong>Return on Equity (ROE):</strong> SLB's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of <strong>5.14%,</strong> the company showcases efficient use of equity capital and strong financial health.</p>
<p><strong>Return on Assets (ROA):</strong> SLB's ROA stands out, surpassing industry averages. With an impressive ROA of <strong>2.22%</strong>, the company demonstrates effective utilization of assets and strong financial performance.</p>
<p><strong>Debt Management:</strong> SLB's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of <strong>0.57</strong>.</p>
<p><a href="https://www.benzinga.com/quote/SLB/earnings"><strong>To track all earnings releases for SLB visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Uncovering Potential: SLB's Earnings Preview

<p>Scotiabank  analyst Phil Hardie   maintains Definity Financial (TSX:<a class="ticker" href="https://www.benzinga.com/stock/DFY#TSX">DFY</a>) with a Sector Outperform and raises the price target from C$61 to C$62.</p>


TSX:DFY

Scotiabank Maintains Sector Outperform on Definity Financial, Raises Price Target to C$62

<p>Phillips 66 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSX#NYSE">PSX</a>) is gearing up to announce its quarterly earnings on Friday, 2025-04-25. Here's a quick overview of what investors should know before the release.</p>
<p>Analysts are estimating that Phillips 66 will report an <strong>earnings per share</strong> (EPS) of $-0.25.</p>
<p>The announcement from Phillips 66 is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.</p>
<p>It's worth noting for new investors that guidance can be a key determinant of stock price movements.</p>
<h3>Historical Earnings Performance</h3>
<p>During the last quarter, the company reported an EPS beat by $0.08, leading to a 0.0% drop in the share price on the subsequent day.</p>
<p>Here's a look at Phillips 66's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>-0.23</td>
<td>1.66</td>
<td>2.55</td>
<td>2.17</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-0.15</td>
<td>2.04</td>
<td>2.31</td>
<td>1.90</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-2.0%</td>
<td>-1.0%</td>
<td>-1.0%</td>
<td>-4.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1745503278_0.png" alt="eps graph" /></p>
<h3>Stock Performance</h3>
<p>Shares of Phillips 66 were trading at $102.78 as of April 23. Over the last 52-week period, shares are down 31.25%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. </p>
<h3>Analysts' Take on Phillips 66</h3>
<p>Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the latest insights on Phillips 66.</p>
<p>Analysts have provided Phillips 66 with 7 ratings, resulting in a consensus rating of Neutral. The average one-year price target stands at $134.29, suggesting a potential 30.66% upside.</p>
<h3>Understanding Analyst Ratings Among Peers</h3>
<p>This comparison focuses on the analyst ratings and average 1-year price targets of Marathon Petroleum, Valero Energy and Sunoco, three major players in the industry, shedding light on their relative performance expectations and market positioning.</p>
<ul>
<li>Analysts currently favor an Outperform trajectory for Marathon Petroleum, with an average 1-year price target of $166.38, suggesting a potential 61.88% upside.</li>
<li>Analysts currently favor an Outperform trajectory for Valero Energy, with an average 1-year price target of $148.5, suggesting a potential 44.48% upside.</li>
<li>Analysts currently favor an Outperform trajectory for Sunoco, with an average 1-year price target of $64.25, suggesting a potential 37.49% downside.</li>
</ul>
<h3>Analysis Summary for Peers</h3>
<p>The peer analysis summary outlines pivotal metrics for Marathon Petroleum, Valero Energy and Sunoco, demonstrating their respective standings within the industry and offering valuable insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Phillips 66</td>
<td>Neutral</td>
<td>-11.98%</td>
<td>$2.11B</td>
<td>0.02%</td>
</tr>
<tr>
<td>Marathon Petroleum</td>
<td>Outperform</td>
<td>-8.60%</td>
<td>$1.75B</td>
<td>2.02%</td>
</tr>
<tr>
<td>Valero Energy</td>
<td>Outperform</td>
<td>-13.15%</td>
<td>$618M</td>
<td>1.13%</td>
</tr>
<tr>
<td>Sunoco</td>
<td>Outperform</td>
<td>-6.59%</td>
<td>$473M</td>
<td>2.50%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>Phillips 66 ranks at the top for Gross Profit and Return on Equity among its peers. However, it ranks at the bottom for Revenue Growth.</p>
<h3>Discovering Phillips 66: A Closer Look</h3>
<p>Phillips 66 is an independent refiner that owns or holds interest in 11 refineries with a total crude throughput capacity of 1.8 million barrels per day, or mmb/d, at the end of 2024. The midstream segment comprises extensive transportation and NGL processing assets. It includes 70,000 miles of crude oil, refined petroleum product, NGL and natural gas pipeline systems, and a comprehensive set of refined petroleum product, NGL and crude oil terminals, gathering and processing plants and fractionation facilities and various other storage and loading facilities. Its CPChem chemical joint venture operates facilities primarily in the United States and the Middle East and produces olefins and polyolefins.</p>
<h3>Key Indicators: Phillips 66's Financial Health</h3>
<p><strong>Market Capitalization Highlights:</strong> Above the industry average, the company's market capitalization signifies a significant scale, indicating strong confidence and market prominence.</p>
<p><strong>Decline in Revenue:</strong> Over the 3 months period, Phillips 66 faced challenges, resulting in a decline of approximately <strong>-11.98%</strong> in revenue growth as of 31 December, 2024. This signifies a reduction in the company's top-line earnings. When compared to others in the Energy sector, the company faces challenges, achieving a growth rate lower than the average among peers.</p>
<p><strong>Net Margin:</strong> Phillips 66's net margin is impressive, surpassing industry averages. With a net margin of <strong>0.02%,</strong> the company demonstrates strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Phillips 66's ROE excels beyond industry benchmarks, reaching <strong>0.02%</strong>. This signifies robust financial management and efficient use of shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of <strong>0.01%,</strong> the company showcases effective utilization of assets.</p>
<p><strong>Debt Management:</strong> The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at <strong>0.73</strong>.</p>
<p><a href="https://www.benzinga.com/quote/PSX/earnings"><strong>To track all earnings releases for Phillips 66 visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Phillips 66's Earnings: A Preview

<p>Stifel Financial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SF#NYSE">SF</a>) underwent analysis by 10 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.</p>
<p>The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">0</td>
<td align="right">5</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>In the assessment of 12-month price targets, analysts unveil insights for Stifel Financial, presenting an average target of $111.2, a high estimate of $135.00, and a low estimate of $84.00. A 10.18% drop is evident in the current average compared to the previous average price target of $123.80. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1745503275_0.png" alt="price target chart" /></p>
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
<p>A clear picture of Stifel Financial's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<p>&#x7C;      Analyst       &#x7C;    Analyst Firm    &#x7C; Action Taken  &#x7C;     Rating      &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C;<br />
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;-----------------&#x7C;--------------------&#x7C;--------------------&#x7C;<br />
&#x7C;Michael Brown       &#x7C;Wells Fargo         &#x7C;Lowers         &#x7C;Overweight       &#x7C;             $102.00&#x7C;$106.00             &#x7C;<br />
&#x7C;Michael Cho         &#x7C;JP Morgan           &#x7C;Lowers         &#x7C;Neutral          &#x7C;             $100.00&#x7C;$123.00             &#x7C;<br />
&#x7C;Bill Katz           &#x7C;TD Cowen            &#x7C;Lowers         &#x7C;Hold             &#x7C;              $84.00&#x7C;$124.00             &#x7C;<br />
&#x7C;Michael Brown       &#x7C;Wells Fargo         &#x7C;Lowers         &#x7C;Overweight       &#x7C;             $106.00&#x7C;$135.00             &#x7C;<br />
&#x7C;Devin Ryan          &#x7C;JMP Securities      &#x7C;Lowers         &#x7C;Market Outperform&#x7C;             $120.00&#x7C;$135.00             &#x7C;<br />
&#x7C;Alexander Blostein  &#x7C;Goldman Sachs       &#x7C;Lowers         &#x7C;Neutral          &#x7C;             $105.00&#x7C;$121.00             &#x7C;<br />
&#x7C;Christopher Allen   &#x7C;Citigroup           &#x7C;Lowers         &#x7C;Neutral          &#x7C;             $105.00&#x7C;$125.00             &#x7C;<br />
&#x7C;Brennan Hawken      &#x7C;UBS                 &#x7C;Raises         &#x7C;Neutral          &#x7C;             $120.00&#x7C;$116.00             &#x7C;<br />
&#x7C;Devin Ryan          &#x7C;JMP Securities      &#x7C;Raises         &#x7C;Market Outperform&#x7C;             $135.00&#x7C;$125.00             &#x7C;<br />
&#x7C;Michael Brown       &#x7C;Wells Fargo         &#x7C;Raises         &#x7C;Overweight       &#x7C;             $135.00&#x7C;$128.00             &#x7C;</p>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Stifel Financial. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Stifel Financial compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
<p>Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Stifel Financial's market position. Stay informed and make well-informed decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/SF/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Stifel Financial analyst ratings.</strong></a></p>
<h2>Get to Know Stifel Financial Better</h2>
<p>Stifel Financial is a middle-market-focused investment bank that produces more than 90% of its revenue in the United States. Approximately 67% of the company's net revenue is derived from its global wealth management division, which supports over 2,000 financial advisors, with the remainder coming from its institutional securities business. Stifel has a history of being an active acquirer of other financial-services firms.</p>
<h3>Financial Milestones: Stifel Financial's Journey</h3>
<p><strong>Market Capitalization Analysis:</strong> The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.</p>
<p><strong>Revenue Growth:</strong> Stifel Financial's revenue growth over a period of 3M has been noteworthy. As of 31 December, 2024, the company achieved a revenue growth rate of approximately <strong>19.21%</strong>. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Financials sector, the company faces challenges, achieving a growth rate lower than the average among peers.</p>
<p><strong>Net Margin:</strong> Stifel Financial's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of <strong>17.41%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Stifel Financial's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of <strong>4.75%,</strong> the company may face hurdles in generating optimal returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of <strong>0.6%,</strong> the company may need to address challenges in generating satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> Stifel Financial's debt-to-equity ratio is below the industry average. With a ratio of <b>0.31</b>, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.</p>
<h2>Analyst Ratings: What Are They?</h2>
<p>Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.</p>
<p>In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


What Analysts Are Saying About Stifel Financial Stock

<p>Centene (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>) is gearing up to announce its quarterly earnings on Friday, 2025-04-25. Here's a quick overview of what investors should know before the release.</p>
<p>Analysts are estimating that Centene will report an <strong>earnings per share</strong> (EPS) of $2.45.</p>
<p>Centene bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Performance in Previous Earnings</h3>
<p>In the previous earnings release, the company beat EPS by $0.31, leading to a 0.91% drop in the share price the following trading session.</p>
<p>Here's a look at Centene's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.49</td>
<td>1.38</td>
<td>2.07</td>
<td>2.08</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.80</td>
<td>1.62</td>
<td>2.42</td>
<td>2.26</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-1.0%</td>
<td>4.0%</td>
<td>8.0%</td>
<td>-2.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1745503269_0.png" alt="eps graph" /></p>
<h3>Stock Performance</h3>
<p>Shares of Centene were trading at $62.12 as of April 23. Over the last 52-week period, shares are down 18.86%. Given that these returns are generally negative, long-term shareholders are likely upset going into this earnings release. </p>
<h3>Insights Shared by Analysts on Centene</h3>
<p>For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on Centene.</p>
<p>Analysts have provided Centene with 3 ratings, resulting in a consensus rating of Neutral. The average one-year price target stands at $68.33, suggesting a potential 10.0% upside.</p>
<h3>Analyzing Ratings Among Peers</h3>
<p>In this analysis, we delve into the analyst ratings and average 1-year price targets of Molina Healthcare, HealthEquity and Alignment Healthcare, three key industry players, offering insights into their relative performance expectations and market positioning.</p>
<ul>
<li>Analysts currently favor an Neutral trajectory for Molina Healthcare, with an average 1-year price target of $368.6, suggesting a potential 493.37% upside.</li>
<li>Analysts currently favor an Outperform trajectory for HealthEquity, with an average 1-year price target of $111.11, suggesting a potential 78.86% upside.</li>
<li>Analysts currently favor an Buy trajectory for Alignment Healthcare, with an average 1-year price target of $18.19, suggesting a potential 70.72% downside.</li>
</ul>
<h3>Summary of Peers Analysis</h3>
<p>The peer analysis summary presents essential metrics for Molina Healthcare, HealthEquity and Alignment Healthcare, unveiling their respective standings within the industry and providing valuable insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Centene</td>
<td>Neutral</td>
<td>3.41%</td>
<td>$3.72B</td>
<td>1.05%</td>
</tr>
<tr>
<td>Molina Healthcare</td>
<td>Neutral</td>
<td>16.04%</td>
<td>$1.11B</td>
<td>5.42%</td>
</tr>
<tr>
<td>HealthEquity</td>
<td>Outperform</td>
<td>18.84%</td>
<td>$189.04M</td>
<td>1.24%</td>
</tr>
<tr>
<td>Alignment Healthcare</td>
<td>Buy</td>
<td>50.68%</td>
<td>$86.34M</td>
<td>-29.00%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>Centene ranks in the middle among its peers for revenue growth, with one peer showing the highest growth. Centene's gross profit is the highest among its peers. However, its return on equity is lower compared to some peers. Overall, Centene's performance is solid but there is room for improvement in return on equity.</p>
<h3>Unveiling the Story Behind Centene</h3>
<p>Centene is a managed care organization that focuses on government-sponsored healthcare plans, including Medicaid, Medicare, and the individual exchanges. Centene served 22 million medical members as of December 2024, mostly in Medicaid (about 60% of membership), the individual exchanges (about 20%), and Medicare (about 5%). The company also has a military contract and provides Medicare Part D pharmaceutical plans.</p>
<h3>Understanding the Numbers: Centene's Finances</h3>
<p><strong>Market Capitalization Analysis:</strong> Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> Centene displayed positive results in 3 months. As of 31 December, 2024, the company achieved a solid revenue growth rate of approximately <strong>3.41%</strong>. This indicates a notable increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.</p>
<p><strong>Net Margin:</strong> Centene's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of <strong>0.69%,</strong> the company may encounter challenges in effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of <strong>1.05%,</strong> the company showcases effective utilization of equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Centene's ROA excels beyond industry benchmarks, reaching <strong>0.34%</strong>. This signifies efficient management of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> Centene's debt-to-equity ratio is below the industry average. With a ratio of <b>0.74</b>, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.</p>
<p><a href="https://www.benzinga.com/quote/CNC/earnings"><strong>To track all earnings releases for Centene visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Centene's Earnings: A Preview

Macro Economic Events

Econ #s

Economics

USA Existing Home Sales (MoM) For March -5.9% Vs -3.0% Est.; 4.4% Prior

WHR stock has given up its prior gain. Whirlpool shares were trading higher after the company issued FY25 adjusted EPS guidance above estimates.

Press Releases

ACM Research Strengthens Atomic Layer Deposition Portfolio with Qualification of Thermal and Plasma-Enhanced ALD Furnace Tools

ACM Research Comments on Updated U.S. Export Restrictions

ACM Research Updates 2024 Revenue Outlook and Provides Initial Outlook for 2025 Revenue

ACM Research to Release Fourth Quarter and Fiscal Year 2024 Financial Results on February 26, 2025

ACM Research Reports Fourth Quarter and Fiscal Year 2024 Results

ACM Research Announces Qualification of High-Temperature SPM Tool for Customer in China

ACM Research to Participate at the 37th Annual ROTH Conference

Management

ACM Research Appoints Charlie Pappis to Board of Directors

ACM Research Receives 2025 3D InCites Technology Enablement Award

ACM Research to Release First Quarter 2025 Preliminary Revenue Range on April 29, 2025 and Full Financial Results on May 8, 2025

ACMR

Axcelis Technologies, Inc. - Common Stock

Axcelis Technologies

Aehr Test System

Applied Mat

Amkor Tech

ASML Holding N.V. - New York Registry Shares

ASML Holding

Atomera

Cohu

DAQO New Energy Corp. American Depositary Shares, each representing five ordinary shares

Comments

ACM Research

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL